Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Aura Biosciences, Inc.NASDAQ: AURA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $300K rose 212.5% year over year, behind the +5279.6% change in trailing-twelve-month financing cash flow. Sequentially, it fell 89.2% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +212.5% toward the trailing-twelve-month pace of +5279.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$300K-89.2% QoQ
Last fiscal yearDec 2025
$77.16M+4737.3% YoY
LTMMar 2026
$77.36M+5279.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+212.5%——
1 year+4737.3%——
3-year CAGR-6.9%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
77.16M USD
Year-over-year change
+4737.3%
4-year CAGR
-17.5%

Financing Cash Flow vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5279.6% is the 3rd highest of 11, against a peer median of +17.3%.
  • Over three fiscal years its annual growth of -6.9% compares with a peer median of +128.2%.
AURA Competitors
Financing Cash Flow for AURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$436.09M USD+91.6%+2614.9%—
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$171.98M USD+5.5%—2258.5%
OCSOculis Holding AGLTM Mar 2026CHF 105.86M CHF-32.9%+370.6%21003.4%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$94.38M USD+72496.9%+9.1%1320.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$77.43M USD+29.1%——
AURAAura Biosciences, Inc.LTM Mar 2026$77.36M USD+5279.6%-6.9%—
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M USD+16083.5%+247.3%44.3%
OCGNOcugen, Inc.LTM Mar 2026$53.56M USD-16.0%-33.7%1199.5%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$47.24M USD+93.8%-8.9%14179.4%
AKTSAktis Oncology, Inc.FY2025$1.21M USD-100.7%—18.7%
BCYCBicycle Therapeutics plcLTM Mar 2026$143.84K USD-100.0%—0.2%
Peer median (excluding AURA) —+17.3%+128.2%1260.2%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
Deferred Income Tax14K0000
Stock-Based Compensation2.31M6.41M8.77M11.72M14.32M
Change in Working Capital(315K)(3.1M)4.44M(2.64M)5.97M
Accounts Receivables00000
Inventory00000
Accounts Payables1.05M340K(1.04M)482K(846K)
Other Working Capital(1.37M)(3.44M)5.48M(3.12M)6.82M
Other Non-Cash Items4K(325K)(1.95M)(3.19M)32K
Operating Cash Flow(32.41M)(54.6M)(63.85M)(79.81M)(84.74M)
Capital Expenditures(2.13M)(1.09M)(709K)(1.25M)(447K)
Acquisitions (Net)066.78K000
Purchases of Investments0(119.78M)(233.65M)(59.11M)(83.96M)
Sales of Investments053.01M120.4M129.18M120M
Other Investing Activities0(66.78K)000
Investing Cash Flow(2.13M)(67.87M)(113.96M)68.82M35.6M
Debt Repayment00000
Common Stock Issued78.7M8.55M3.17M1.6M77.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities334K430K1.5M00
Financing Cash Flow166.26M95.63M97.29M1.6M77.16M
Effect of Forex Changes0000(186K)
Net Change in Cash131.72M(26.84M)(80.52M)(9.39M)27.82M
Free Cash Flow(34.54M)(55.7M)(64.56M)(81.06M)(85.19M)

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.